Stueland Katherine, chief executive officer of GeneDx (WGS), has filed 73 Form 4 transactions in the company, all of them sells or option exercises. Her total open-market sales reached $16,046,981.26, with no open-market purchases on record. The only acquisition activity, $299,926.44, came through option exercises coded M, which are mechanical events rather than discretionary buys.
The recent pattern is consistent. On September 16, 2026, Stueland executed five separate sales totaling $1,025,012.87, paired with an option exercise. That followed a September 9 sale of $310,932.12 and a June 16 cluster of three sales worth $638,104.42. The largest single-day activity came on March 26, 2026, when she sold $2,964,841.37 across five transactions. Smaller sales occurred on June 9, April 29, and March 16, with values ranging from $1,154.16 to $711,089.84.
The data shows a clear selling bias. Every open-market transaction in the recent window is coded S, and the dollar amounts are substantial relative to the compensation-derived acquisitions. The option exercises, all valued at zero, appear to be routine conversions that immediately precede or coincide with sales. There is no evidence of buying conviction in any filing. The sales are spread across multiple dates in 2026, suggesting a scheduled or systematic disposition rather than a one-off event.
AI-assisted summary